Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Our report is an authoritative Owner’s Manual on the company.
- A vital piece in the investor’s toolbox, our report allows you to uncover the essence of the business
- We pinpoint strengths and weaknesses; discuss strategy
- Our aim is to make deep knowledge about the company readily available, saving investors time and enabling dialogue

We offer our research as a service for Japanese corporates.
- Our in-depth reports allow them to better inform investors by presenting an unbiased third-party view of business fundamentals
- Our reports do not offer investment opinions and are free for all investors

We start our coverage with a substantial core report.
- We continuously update this report to reflect earnings, news flow, and any material developments
- We thoroughly interview management on a quarterly basis

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>Sales for Q2 FY12/24 were JPY316mn (-36.9% YoY), with an operating loss of JPY24mn, and sales progress at 34.1%.</li><li>Drug Discovery and Development segment recorded no sales, with an operating loss of JPY1.1bn, and increased R&D spending by 3.4% YoY.</li><li>Full-year forecast includes JPY925mn sales (+0.8% YoY) and JPY229mn operating profit (+1.8% YoY) for Drug Discovery Support segment.</li></ul>

Sales for Q2 FY12/24 were JPY316mn (-36.9% YoY), with an operating loss of JPY24mn, and sales progress at 34.1%.Drug Discovery and Development segment recorded no sales, with an operating loss of JPY1.1bn, and increased R&D spending by 3.4% YoY.Full-year forecast includes JPY925mn sales (+0.8% YoY) and JPY229mn operating profit (+1.8% YoY) for Drug Discovery Support segment.

カルナバイオサイエンス（4572 JP）：2024年12月期上期決算速報

Carna Biosciences

カルナバイオサイエンス（4572 JP）：2024年12月期上期決算速報